Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) EBT: 2014-2024

Historic EBT for Spyre Therapeutics (SYRE) over the last 11 years, with Dec 2024 value amounting to -$208.0 million.

  • Spyre Therapeutics' EBT rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.66%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.62% up from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' EBT is -$208.0 million, which was up 38.62% from -$338.8 million recorded in FY2023.
  • In the past 5 years, Spyre Therapeutics' EBT registered a high of -$65.7 million during FY2021, and its lowest value of -$338.8 million during FY2023.
  • In the last 3 years, Spyre Therapeutics' EBT had a median value of -$208.0 million in 2024 and averaged -$210.2 million.
  • In the last 5 years, Spyre Therapeutics' EBT slumped by 303.59% in 2023 and then soared by 38.62% in 2024.
  • Spyre Therapeutics' EBT (Yearly) stood at -$80.9 million in 2020, then rose by 18.83% to -$65.7 million in 2021, then fell by 27.86% to -$84.0 million in 2022, then tumbled by 303.59% to -$338.8 million in 2023, then surged by 38.62% to -$208.0 million in 2024.